Benefits
Blood sugar support (open-label decoction trial)
A trial conducted by the Indian Council of Medical Research (ICMR) tested P. marsupium decoction in newly-diagnosed non-insulin-dependent diabetes mellitus (NIDDM) patients, measuring blood glucose and HbA1c. This was an open-label trial (no placebo) of a decoction of the plant, a different preparation than this branded pterostilbene extract, which has not itself been tested for blood-sugar efficacy.
Pterostilbene — more bioavailable than resveratrol
Pterostilbene is structurally a di-methylated version of resveratrol but with better bioavailability, potency, and metabolic stability. The methylation increases lipid solubility and resistance to first-pass metabolism. Practical advantage over resveratrol which has poor oral bioavailability (<1% in some studies). Same molecular target class but better drug-like properties.
Antioxidant activity (laboratory studies)
In test-tube assays, pterostilbene resisted lipid peroxidation more than resveratrol. This is laboratory chemistry, not a measured human antioxidant outcome. In the one human trial of Silbinol, the serum antioxidant profile did not differ significantly from placebo, although glutathione trended higher.
PPARα induction (preclinical mechanism)
Pterostilbene shows the highest induction of PPAR-alpha among stilbenes. PPAR-alpha regulates fatty acid metabolism and lipid handling. This is a laboratory mechanism, not a measured human outcome, and the human safety trial of Silbinol found no change in blood lipids. The drug comparison to fenofibrate comes from preclinical work.
Insulin sensitivity improvement
In animal and cell studies, pterostilbene and the (-)-epicatechin component affected insulin signaling. This is preclinical work; no human trial of Silbinol has measured insulin sensitivity, and the comparison to metformin comes from animal data. Combined mechanisms address both insulin sensitivity (cells responding to insulin) and insulin secretion.
Antimicrobial activity (laboratory studies only)
Pterostilbene has shown antimicrobial activity in laboratory tests. These are cell and culture studies, not trials in people, and this has not been tested as a benefit of the supplement in humans.
Anti-inflammatory (COX-2 inhibition)
Pterostilbene has documented anti-inflammatory effects via COX-2 inhibition, the same target class as NSAIDs. The mechanism supports applications in inflammatory metabolic disease (chronic low-grade inflammation drives metabolic syndrome). It also has analgesic effects.
TMAO effects (preclinical)
Pterostilbene has been examined for effects on trimethylamine N-oxide (TMAO) in preclinical work. No human trial of Silbinol has measured TMAO or any cardiovascular outcome.
Safety established — 200 mg/day clinical trial
A safety trial gave healthy adults Silbinol 90% pterostilbene 100 mg twice daily (200 mg/day) or placebo for 2 months. Hematological, lipid, glycemic, thyroid, liver, and renal function parameters remained within normal range, with no serious adverse events. Trial registration CTRI/2019/08/020736.
Mechanism of action
PPARα activation
Pterostilbene induces PPARα in laboratory studies. PPARα regulates fatty acid oxidation and lipid metabolism, and the comparison to fibrate drugs (fenofibrate) comes from preclinical work. This is a mechanism, not a human outcome: the one human trial of Silbinol found no change in blood lipids.
Insulin signaling enhancement
(-)-Epicatechin in Silbinol has documented insulin-like activity — directly supporting insulin signaling. Combined with pterostilbene's effects on insulin sensitivity, Silbinol addresses multiple aspects of glucose homeostasis. Comparative studies confirm similarity between (-)-epicatechin and insulin mechanisms.
COX-2 anti-inflammatory inhibition
Pterostilbene inhibits cyclooxygenase-2 (COX-2) — the inflammatory isoform of the enzyme producing prostaglandins. Same target as NSAIDs (with milder magnitude). Mechanism reduces inflammatory contribution to metabolic and cardiovascular disease.
Lipid peroxidation prevention
Pterostilbene's antioxidant activity exceeds resveratrol against lipid peroxidation. Lipid peroxidation drives atherosclerosis via oxidized LDL formation. Preventing lipid peroxidation supports cardiovascular health alongside the direct lipid-lowering effects.
Methylation-enhanced bioavailability
Pterostilbene's two methyl groups (vs resveratrol's hydroxyl groups) increase lipid solubility and resistance to phase II metabolism (glucuronidation, sulfation). Animal pharmacokinetic work reported markedly higher oral bioavailability for pterostilbene (around 80 percent in rats) than for resveratrol (commonly under 1 percent). The bioavailability advantage explains why pterostilbene produces effects at lower doses than resveratrol.
Clinical trials
Randomized double-blind placebo-controlled study evaluating Silbinol® at 100 mg twice daily (200 mg/day) for 2 months in healthy adults. Primary outcomes: changes in laboratory parameters, vital signs, adverse events. Secondary: serum antioxidant enzyme levels. Published in peer-reviewed journal. CTRI/2019/08/020736.
60 healthy adult participants (27 males, 33 females). 2-month intervention with 100 mg Silbinol bid or placebo.
Hematological, lipid, glycemic, thyroid profiles, liver and renal functions remained within normal range — no differences between groups. No serious adverse events. The serum antioxidant profile did not differ significantly between groups, although glutathione levels trended higher in the pterostilbene group. Established safety of >90% pterostilbene at 200 mg/day for human use. Foundation for therapeutic applications.
Phase 2 open trial conducted by the Indian Council of Medical Research (ICMR) at 4 centers in India testing P. marsupium decoction for 12 weeks in newly-diagnosed non-insulin-dependent diabetes mellitus (NIDDM) patients. Foundational efficacy evidence. Published in Indian Journal of Medical Research.
93 newly-diagnosed NIDDM patients. 12-week intervention with P. marsupium decoction.
Documented improvements in blood glucose levels and glycosylated hemoglobin (HbA1c) with P. marsupium intervention. Foundational evidence supporting Silbinol's metabolic positioning. Traditional decoctions and modern standardized extracts provide consistent antidiabetic effects in NIDDM patients.
Class evidence for pterostilbene pharmacology across preclinical and clinical research. Studies include Rimando et al. (PPARα induction), Manickam et al. (insulin sensitivity), Remsberg et al. (analgesic), Satheesh and Pari (antidiabetic mechanism), and others.
Various — animal models and in vitro studies of pterostilbene pharmacology.
Pterostilbene consistently demonstrates: PPARα activation (highest among stilbenes), insulin sensitivity effects, anti-inflammatory activity via COX-2 inhibition, antioxidant activity in vitro, and antimicrobial activity in culture, all observed in animal or cell models rather than human trials. Multi-mechanism profile supports broad applications across metabolic, cardiovascular, and inflammatory health.